Is TNF really involved in cachexia?

Cancer Investigation

Volumn 15, Issue 1, 1997, Pages 47-54

  García Martínez, Cèlia ^a   Costelli, Paola ^b   López Soriano, Francisco J ^a   Argilés, Josep M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

CACHEXIA; CANCER; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 1842417148     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909709018916     Document Type: Review

References (81)

1. Aderka D, Fisher D, Levo Y, Holtmann H, Hahn T, Wallach D: Cachectin/tumour necrosis factor production by cancer patients. Lancet 2:1190, 1985.
2. Aderka D, Engelmann H, Hornik V, Skornick Y, Levo Y, Wallach D, Kushtai G: Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res 51:5602-5607, 1991.
3. Aggarwal BB, Kohr WJ, Haas PE, Moffat B, Spencer SA, Henzel WJ, Bringman TS, Nedwin GE, Goeddel DV, Harkins RN: Human tumor necrosis factor: Production, purification and characterization. J Biol Chem 260:2345-2354, 1985.
4. Algire GH, Legallais FY, Anderson BF: Vascular reactions of normal and malignant tissues in vivo. V. The role of hypotension in the action of a bacterial polysaccharide on tumors. J Natl Cancer Inst 12:1279-1295, 1952.
5. 14C]isobutyrate. Biochem J 261:357-362, 1989.
6. Argilés JM, García-Martínez C, Llovera M, López-Soriano FJ: The role of cytokines in muscle wasting: Its relation with cancer cachexia. Med Res Rev 12:637-652, 1992.
7. Balkwill F, Burke F, Talbot D, Tavernier J, Osborne R, Naylor S, Durbin H, Fiers W: Evidence for tumour necrosis factor/cachectin production in cancer.Lancet 2:1229-1232, 1987.
8. Beck SA, Smith KL, Tisdale, MJ: Anticachectic and antitumor effect of eicosapentaenoic acid and its effects on protein turnover. Cancer Res 51:6089-6093, 1991.
9. Beutler B, Mahoney J, LeTrang N, Pekala, P, Cerami A: Purification of cachectin, a lipoprotein lipase suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med 161:984-995, 1985a.
10. Beutler B, Milsark IV, Cerami A: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869-371, 1985b.
11. Beutler B, Cerami A: The history, properties, and biological effects of cachectin. Biochemistry 27:7575-7582, 1988.
12. Billiau A, Matthys P: Interferon-γ: More of a cachectin than tumor necrosis factor. Cytokine 4:259-263, 1992.
13. Brenner DA, Buck M, Feitelberg SP, Chojkier M: Tumour necrosis factor-alpha inhibits albumin gene expression in a murine model of cachexia. J Clin Invest 85:248-255, 1990.
14. Carbó N, Costelli P, Tessitore L, Bagby GJ, López-Soriano FJ, Baccino FM, Argilés JM: Anti-tumour necrosis factor-α treatment interferes with changes in lipid metabolism in a tumour cachexia model. Clin Sci 87:349-355, 1994.
15. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72:3666-3670, 1975.
16. Cerami A, Ikeda Y, Trang LN, Hotez PJ, Beutler B: Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: The role of cachectin (tumor necrosis factor). Immunol Lett 11:173-177, 1985.
17. Charters Y, Grimble RF: Effect of recombinant human tumour necrosis factor-α on protein synthesis in liver, skeletal muscle and skin of rats. Biochem J 258:493-497, 1989.
18. Cheng I, Turksen K, Yu QC, Schreiber H, Teng M, Fuchs E: Cachexia and graft-versus-host-disease type skin changes in keratin promoter-driven-alpha transgenic mice. Genes Dev 6:1444-1456, 1992.
19. Coley WB: Contribution to the knowledge of sarcoma: The treatment of sarcoma by inoculation with erysipelas,with a report of three recent cases. Ann Surg 14:210-220, 1891.
20. Costelli P, Carbó N, Tessitore L, Bagby GJ, López-Soriano FJ, Argilés JM, Baccino FM: Tumor necrosis factor-α mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest 92:2783-2789, 1993.
21. Darling G, Fraker DL, Jensen CJ, Gorschboth CM, Norton JA: Cachectic effects of recombinant human tumor necrosis factor in rats. Cancer Res 50:4008-4013, 1990.
22. Darlington GJ, Wilson DR, Lachman LB: Monocyte-conditioned medium, interleukin-1 and tumour necrosis factor stimulate the acute phase response in human hepatoma cells in vitro. J Cell Biol 130:787-793, 1986.
23. Feingold KR, Grunfeld C: Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo. J Clin Invest 80:184-190, 1987.
24. Fiedler UB, Loof I, Sander E, Voehringer V, Galanos C, Fournel MA: Monoclonal antibody to tumor necrosis factor-α prevents lethal endotoxin sepsis in adult rhesus monkeys. J Lab Clin Med 120:574-588, 1992.
25. Fong Y, Moldawer LL, Marano M, Wei H, Barber A, Manogue K, Tracey KJ, Kuo G, Fishman DA, Cerami A, Lowry SF: Cachectin/TNF or IL-1α induces cachexia with redistribution of body proteins. Am J Physiol 256:R659-R665, 1989.
26. Frei E, Spriggs D: Tumor necrosis factor: Still a promising agent. J Clin Oncol 7:291-294, 1989.
27. Freudenberg MA, Galanos C: Tumor necrosis factor-alpha mediates lethal activity of killed gram-negative and gram-positive bacteria in D-galactosamine-treated mice. Infect Immun 59:2110-2115, 1991.
28. García-Martínez C, López-Soriano FJ, Argilés JM: Acute treatment with tumour necrosis factor-α induces changes in protein metabolism in rat skeletal muscle. Mol Cell Biochem 125:11-18, 1993.
29. García-Martínez C, Llovera M, Agell N, López-Soriano FJ, Argilés JM: Ubiquitin gene expression in skeletal muscle is increased by tumor necrosis factor-α. Biochem Biophys Res Commun 201:682-686, 1994.
30. Goodman MN: Tumor necrosis factor induces skeletal muscle protein breakdown in rats. Am J Physiol 260:E727-E730, 1991.
31. Grau GE, Fajardo LF, Piguet PF, Allet B, Lambert PH, Vassalli P: Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science 237:1210-1212, 1987.
32. Greenberg AS, Nordan RP, McIntosh J, Calvo JC, Scow RO, Jablons D: Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: A possible role for interleukin 6 in cancer cachexia. Cancer Res 52:4113-4116, 1992.
33. Grunfeld C, Palladino MA: Tumor necrosis factor: Immunologic, anti-tumor, metabolic and cardiovascular activities. Adv Intern Med 35:45-71, 1990.
34. Horvath CJ, Desrosiers RC, Sehgal PK, King NW, Ringler DJ: Effect of simian immunodeficiency virus infection on tumor necrosis factor-α production by alveolar macrophages. Lab Invest 65:280, 1991.
35. Kawakami M, Cerami A: Studies on endotoxin-induced decrease in lipoprotein lipase activity. J Exp Med 154:631-639, 1981.
36. Keffler J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G: Transgenic mice expressing human tumor necrosis factor: A predictive model of arthritis. EMBO J 10:4025-4031, 1991.
37. Lawson DH, Richmond A, Nixon DW, Rudman D:Metabolic approaches to cancer cachexia. Annu Rev Nutr 2:277-301, 1982.
38. Lee MD, Zentella A, Vine W, Pekala PH, Cerami A: Effect of endotoxin-induced monokines on glucose metabolism in the muscle cell line L6. Proc Natl Acad Sci USA 84:2590-2594, 1987.
39. Lewis M, Tartaglia LA, Lee A, Bennett GL, Rice GC, Wong GHW, Chen EY, Goeddel DV: Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci USA 88:2830-2834, 1991.
40. Llovera M, López-Soriano FJ, Argilés JM: Effects of tumor necrosis factor-α (TNF) on muscle-protein turnover in female Wistar rats. J Natl Cancer Inst 85:1334-1339, 1993.
41. Llovera M, García-Martínez C, Agell N, Marzábal M, López-Soriano FJ, Argilés JM: Ubiquitin gene expression is increased in skeletal muscle of tumour-bearing rats. FEBS Lett 338:311-318, 1994.
42. Llovea M, García-Martínez C, Agell N, López-Soriano FJ, Argilés JM: Muscle wasting associated with cancer cachexia is linked to an important activation of the ATP-dependent ubiquitin-mediated proteolysis. Int J Cancer 61:138-141, 1995.
43. Mahony SM, Tisdale MJ: Induction of weight loss and metabolic alterations by human recombinant tumour necrosis factor. Br J Cancer 58:345-349, 1988.
44. Mahony SM, Beck SA, Tisdale MJ: Comparison of weight loss induced by recombinant tumour necrosis factor with that produced by a cachexia inducing tumour. Br J Cancer 57:385-389, 1988.
45. Matthys P, Heremans H, Opdenakker G, Billiau A: Anti-interferon-γ antibody treatment, growth of Lewis Lung tumours in mice and tumour-associated cachexia. Eur J Cancer 27:182-187, 1991a.
46. Matthys P, Dukmans R, Proost P, Van Damme J, Heremans H, Sobis H, Billiau A: Severe cachexia in mice inoculated with interferon-γ-producing tumor cells. Int J Cancer 49:77-82, 1991b.
47. Maury CPJ, Teppo AM: Raised serum levels of cachectin/tumor necrosis factor-α in renal allograft rejection. J Exp Med 166:1132-1137, 1987.
48. Mészaros K, Lang CH, Bagby GJ, Spitzer JJ: Tumor necrosis factor increases in vivo glucose utilization of macrophage rich tissues. Biochem Biophys Res Commun 149:1-6, 1987.
49. Mészaros K, Lang CH, Bagby GJ, Spitzer JJ: In vivo glucose utilization by individual tissues during nonlethal hypermetabolic sepsis. FASEB J 2:3983-3986, 1988.
50. Michie HR, Sherman, ML, Spriggs DR, Rounds J, Christie M, Wilmore DW: Chronic TNF infusion causes anorexia but not accelerated nitrogen loss. Ann Surg 209:19-24, 1989.
51. Moldawer LL, Droitt C, Lundholm K: Monocytic production and plasma bioactivities of interleukin-1 and tumour necrosis factor in human cancer. Eur J Clin Invest 18:486-492, 1988.
52. Mori M, Yamaguchi K, Honda S, Nagasaki K, Ueda M, Abe O, Abe K: Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor. Cancer Res 51:6656-6659, 1991.
53. Morrison SD: Cancer cachexia. In: Influence of Tumor Development on the Host, edited by AL Liotta, Amsterdam, Netherlands, Kluwer Acad. Publ., 1989, pp 176-213.
54. Mullen BJ, Harris RBS, Patton JS, Martin RJ: Recombinant tumor necrosis factor alpha chronically administered in rats: Lack of cachectin effects. Proc Soc Exp Biol Med 193:318-325, 1990.
55. Muto Y, Meager A, Eddleston ALWF, Nouri-Aria KT, Alexander GJM, Williams R: Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet 2:72-74, 1988.
56. Nelson S, Bagby GJ, Bainton BG, Wilson LA, Thompson JJ, Summer WR: Compartmentalization of intra-alveolar and systemic lipopolysaccharide-induced tumor necrosis factor and the pulmonary inflammatory response. J Infect Dis 159:888-894, 1989.
57. Oliff A, Defeo-Jones D, Boyer M, Martinez D, Keifer D, Vuocolo G, Wolfe A, Socher SH: Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 50:555-563, 1987.
58. Pape ME, Kim KH: Effect of tumor necrosis factor on acetyl-coenzyme A carboxylase gene expression and pre-adipocyte differentiation. Mol Endocrinol 2:395-403, 1988.
59. Pekala PH, Price SR, Horn, CA, Horn BE, Moss J, Cerami A: Selective inhibition of synthesis of enzymes for de novo fatty acid biosynthesis by an endotoxin-induced mediator from exudate cells. Proc Natl Acad Sci USA 80:2743-2747, 1983.
60. Pennica D, Hayflick JS, Bringman TS, Palladino MA, Goeddal DV: Clonning and expression in E. coli of the cDNA for murine tumour necrosis factor. Proc Natl Acad Sci USA 82:6060-6064, 1985.
61. Perlmutter DH, Dinarello CA, Punsa PJ, Colten HR: Cachectin/tumor necrosis factor regulates hepatic acute phase gene expression. J Clin Invest 78:1349-1354, 1986.
62. Remick DG: Significance of in vivo detection of tumor necrosis factor. Lab Invest 65:259-260, 1991.
63. Rouzer C, Cerami A: Hypertriglyceridemia associated with Trypanosoma brucei brucei infection in rabbits: Role of defective triglyceride removal. Mol Biochem Parasitol 2:31-38, 1980.
64. Saarinen UM, Koskelo E-K, Teppo AM, Simes MA: Tumor necrosis factor in children with malignancies. Cancer Res 50:592-595, 1990.
65. Scuderi P, Lam KS, Ryan KJ, Petersen E, Sterling KE, Finley PR, Ray GC, Slymen DJ, Salmon SE: Raised serum levels of tumour necrosis factor in parasitic infections. Lancet 2:1364-1365, 1986.
66. Selby PJ, Hobbs, S, Viner C, Jackson E, Smith IE, McElwain TJ: Endogenous tumour necrosis factor in cancer patients. Lancet 1:483, 1988.
67. Semb H, Peterson J, Tavernier J, Olivecrona T: Multiple effects of tumor necrosis factor of lipoprotein lipase in vivo. J Biol Chem 262:8390-8394, 1987.
68. Sherry B, Cerami A: Cachectin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory response. J Cell Biol 107:1269-1277, 1988.
69. Sherry BA, Gelin J, Fong Y, Marano M, Wei H, Cerami A, Lowry SF, Lundholm K, Moldawer LL: Anticachectin/tumor necrosis factor-α antibodies attenuate development of cachexia in tumor model. FASEB J 3:1956-1962, 1989.
70. Socher SH, Martinez D, Craig JB, Kuhn JG, Oliff A: Tumour necrosis factor nondetectable in patients with cancer cachexia. J Natl Cancer Inst 80:595-598, 1988.
71. Stovroff MC, Fraker DL, Norton JA: Cachectin activity in the serum of cachectic, tumor-bearing rats. Arch Surg 124:94-99, 1988.
72. Strassmann G, Fong M, Kenney JS, Jacob CO: Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 89:1681-1684, 1992.
73. Tisdale MJ: Newly identified factors that alter host metabolism in cancer cachexia. Trends Pharmacol Sci 11:473-475, 1990.
74. Torti FM, Dieckmann B, Beutler B, Cerami A, Ringold GM: A macrophage factor inhibits adipocytes gene expression: An in vitro model of cachexia. Science 229:867-869, 1985.
75. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A: Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662-664, 1987.
76. Tracey KJ, Wei H, Manogue KR, Fong Y, Hesse DG, Nguyen HT, Cotran RS, Cerami A, Lowry SF: Cachectin/TNF induces cachexia, anemia, and inflammation. J Exp Med 167:1211-1227, 1988.
77. Tracey KJ, Morgello S, Koplin B, Fahey TJ, Fox J, Aledo A, Manogue KR, Cerami A: Metabolic effects of cachectin/tumor necrosis factor are modified by site of production: Cachectin/tumor necrosis factor-secreting tumor in skeletal mucle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia. J Clin Invest 86:2014-2024, 1990.
78. Waage A, Espevik T, Lamvik J: Detection of tumour necrosis factor-like cytotoxicity in serum from patients with septicaemia but not from untreated cancer patients. Scand J Immunol 24:739-743, 1986.
79. Waage A, Halstensen A, Espevik T: Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 2:355-357, 1987.
80. Waage A, Halstensen A, Shalaby R, Brandtzaeg P, Kierulf P, Espevik T: Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6 in meningococcal meningitis: Relation to the inflammatory response. J Exp Med 170:1859-1865, 1989.
81. Zugmaier G, Paik S, Wilding G, Knabbe K, Bano M, Lupu R, Deschauer B, Simpson S, Dickson RB, Lippman M: Transforming growth factor β1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice. Cancer Res 51:3590-3594, 1991.